For Doctors in a Hurry
- Clinicians lack real-world data on the safety and effectiveness of transcatheter tricuspid valve replacement for severe tricuspid regurgitation.
- This retrospective study analyzed 1034 consecutive patients who underwent the procedure at 82 centers between February 2024 and March 2025.
- At 30 days, 97.7% of patients achieved mild or less regurgitation, with a 3.1% all-cause mortality rate.
- The researchers concluded that the procedure provides effective valve replacement and significant functional improvements in older, comorbid patient populations.
- These findings support the clinical utility of this procedure, showing consistent safety profiles and improved health status across diverse settings.
Addressing the Forgotten Valve in High-Risk Patients
Severe tricuspid regurgitation has historically been an undertreated condition, frequently associated with significant morbidity and mortality in older adults who are often poor candidates for conventional surgery [1, 2]. While surgical tricuspid valve replacement carries an operative mortality rate as high as 12 percent, many patients remain symptomatic despite optimal medical therapy [3, 4]. The emergence of transcatheter tricuspid valve replacement offers a less invasive alternative for those at high surgical risk, aiming to improve functional capacity and reduce heart failure hospitalizations [5]. Clinical guidelines emphasize the need for individualized management strategies in valvular heart disease, yet the transition from controlled trial environments to routine clinical practice remains a critical hurdle for new technologies [6]. A recent analysis of a national registry now provides essential data on how this intervention performs in a real-world setting.
Registry Data Reflect an Older Comorbid Population
To evaluate the performance of transcatheter tricuspid valve replacement in routine clinical practice, researchers conducted a retrospective cohort study of 1034 attempted procedures performed at 82 centers across the United States. This analysis included all consecutive patients who underwent the procedure from February 2024 through March 2025, with data sourced directly from the Society of Thoracic Surgeons and the American College of Cardiology Transcatheter Valve Therapy Registry. The statistical analysis for this cohort was conducted between September 2025 and February 2026 to assess early safety and efficacy outcomes outside the controlled environment of a randomized trial. This real-world evidence is vital for clinicians, as registry data often capture a more heterogeneous and medically complex patient population than the highly selected participants found in pivotal clinical trials.
High Procedural Success and Sustained Valve Competence
The technical feasibility of transcatheter tricuspid valve replacement in this real-world cohort was high, addressing historical concerns regarding the anatomical complexity and variability of the tricuspid apparatus. Among the 1034 attempted procedures analyzed in the registry, a valve was successfully implanted in 1017 patients, representing a 98.4% success rate. This high rate of procedural success suggests that the technology is reproducible across the 82 participating centers, even when treating an older population with the significant comorbidities and anatomical challenges typical of end-stage tricuspid disease. The mean age of the cohort was 77.1 years (standard deviation of 10.6 years), and 69.1% of the patients were female. Clinicians should note the significant disease burden present at baseline: all 1034 patients suffered from symptomatic, severe tricuspid regurgitation that persisted despite the use of optimal medical therapy. Furthermore, 73.2% of the patients were in New York Heart Association functional class III or IV at the time of the intervention, indicating that nearly three-quarters of the population experienced marked or severe limitations in physical activity due to heart failure symptoms before undergoing the procedure.
Beyond the technical success of the implantation itself, the immediate hemodynamic impact on valvular function was nearly universal. The researchers reported that mild or less tricuspid regurgitation was achieved in 98.4% of patients post-procedure, a critical metric for clinicians managing the right-sided heart failure symptoms and systemic venous congestion associated with severe valvular incompetence. This near-total elimination of regurgitant flow is essential for unloading the right ventricle and potentially halting the progression of congestive hepatopathy and renal dysfunction often seen in these patients. The durability of this valvular competence remained stable through the early follow-up period, which is a key consideration for short-term prognosis and recovery. Data from the registry indicated that mild or less tricuspid regurgitation was maintained in 97.7% of patients at 30 days. This sustained reduction in regurgitation in the vast majority of the cohort provides a physiological basis for the functional improvements observed in the study, suggesting that the transcatheter approach effectively restores tricuspid valve function in a routine clinical setting outside of highly controlled trial environments.
Safety Profile and Conduction System Considerations
The safety profile of transcatheter tricuspid valve replacement in this real-world registry aligns with the results that led to its regulatory approval in the US in 2024, which followed the TRISCEND II randomized clinical trial. For clinicians managing high-risk patients, the early postoperative period is critical for assessing procedural risk versus functional benefit. In this cohort of 1034 patients, the all-cause mortality rate at 30 days was 3.1%, a figure that reflects the complexity of treating an older, comorbid population with advanced valvular disease. Furthermore, the incidence of major neurological complications remained low, with the 30-day stroke rate reported at 0.2%. These findings suggest that the embolic risks associated with large-bore transcatheter interventions in the right heart are manageable in routine clinical practice.
Beyond mortality and stroke, the study quantified common post-procedural complications that impact long-term management and hospital length of stay. The researchers found that the 30-day bleeding rate was 7.9%, while the rate of heart failure hospitalization at 30 days was 3.1%. Notably, these rates of bleeding were lower than those reported in the TRISCEND II randomized clinical trial, suggesting that as centers gain experience with the device and patient selection, the safety profile may continue to refine. This reduction in bleeding events is particularly relevant for the tricuspid population, who often require chronic anticoagulation and possess fragile vascular structures. A primary concern with any tricuspid intervention is the proximity of the valve to the conduction system, which can necessitate the use of permanent pacing. In this registry, new cardiac implantable electronic device (CIED) implantation occurred in 15.9% of CIED-naive patients at 30 days. While this represents a significant minority of patients requiring a new pacemaker or defibrillator, the researchers noted that the rates of new CIED implantation were lower than those observed in the TRISCEND II randomized clinical trial. This suggests that real-world implantation techniques or patient anatomical considerations may be mitigating some of the conduction system interference previously seen in controlled trial settings. For the practicing cardiologist, these data provide a clear framework for counseling patients on the expected 30-day risks, balancing a 98% procedural success rate against the roughly 16% chance of requiring a new conduction device.
Rapid Gains in Functional Status and Quality of Life
The primary clinical objective for patients undergoing transcatheter tricuspid valve replacement is the alleviation of debilitating symptoms such as peripheral edema and fatigue. In this registry, the reduction in tricuspid regurgitation translated into rapid and substantial improvements in functional capacity. At the 30-day follow-up, 82.7% of patients reached New York Heart Association functional class I or II (P < .001), representing a marked shift from the baseline where 73.2% of the cohort was in class III or IV. This transition indicates that the vast majority of patients moved from having marked limitations in physical activity to having mild or no symptoms during ordinary exertion within one month of the procedure. Beyond clinician-assessed functional class, the researchers utilized the Kansas City Cardiomyopathy Questionnaire Overall Summary score, which is a validated 100-point scale used to quantify a patient's symptoms, physical limitations, social interference, and quality of life. The study found that the mean Kansas City Cardiomyopathy Questionnaire Overall Summary score improved by 22.4 points from baseline to 30 days (P < .001). In the context of heart failure management, a change of 20 points or more is typically regarded as a very large clinical improvement, suggesting that the elimination of severe tricuspid regurgitation provides a perceptible and significant benefit to the patient's daily lived experience.
Clinicians often express concern regarding how pre-existing cardiac hardware might influence the success of tricuspid interventions. To address this, the researchers performed a subgroup analysis comparing patients with and without baseline cardiac implantable electronic devices, such as pacemakers or defibrillators. The analysis confirmed that the presence of these devices did not compromise the short-term benefits of the procedure. Specifically, there were no significant differences in 30-day mortality (P = .47), heart failure hospitalization (P > .99), or functional outcomes (P = .55) when patients were stratified by baseline cardiac implantable electronic device status. These findings suggest that transcatheter tricuspid valve replacement is an effective intervention for symptomatic relief regardless of whether a patient has pre-existing trans-tricuspid leads, providing reassurance to clinicians managing this common clinical scenario.
References
1. Azami P, Hosseinpour A, Kamalpour J, et al. Efficacy and Safety of Transcatheter Tricuspid Valve Replacement in Patients With Moderate to Severe Tricuspid Regurgitation: A Systematic Review and Meta-Analysis on Clinical Outcomes and Echocardiographic Indices.. Health science reports. 2025. doi:10.1002/hsr2.70950
2. Buğan B, Çekirdekçi Eİ, Onar LÇ, Barçın C. Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: A Systematic Review and Meta-analysis.. Anatolian journal of cardiology. 2022. doi:10.5152/AnatolJCardiol.2022.1440
3. Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022. doi:10.4244/EIJ-D-22-00442
4. Arnold SV, Hahn RT, Thourani V, et al. Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial.. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.10.067
5. Hatab T, Badwan O, Alkhatib R, et al. Clinical Outcomes Following Transcatheter Tricuspid Valve Replacement - A Meta-Analysis.. Structural heart : the journal of the Heart Team. 2025. doi:10.1016/j.shj.2025.100721
6. Members AF, Vahanian A, Alfieri O, et al. Guidelines on the management of valvular heart disease (version 2012). European Heart Journal. 2012. doi:10.1093/eurheartj/ehs109
